STADA - Corporate history

2011

• Purchase of a branded product portfolio for the EU markets in Central Europe successfully concluded
• Purchase of a generics business in Switzerland successfully concluded
• STADA acquires British branded product Cetraben^®

2010

• Market capitalization on December 31, 2010: EUR 1.49 billion / Enterprise value:
  approx: EUR 2.4 billion

2009

• Market capitalization on December 31, 2009: EUR 1.42 billion / Enterprise value:
  approx: EUR 2.3 billion

2008

• Sales at record level for the thirteenth time in a row
• Market capitalization on December 31, 2008: EUR 1.20 billion / Enterprise value:
  approx: EUR 2,2 billion

2007

• Acquisition of the British Forum Bioscience group
• Acquisition of the Russian MAKIZ group

2006

• Acquisition of the Serbian Hemofarm Group
• Sale of US subsidiary

2005

• Acquisition of a package of eleven European branded products (amongst others Mobilat^®)
• STADA acquired a 58% stake in the Chinese pharmaceuticals manufacturing company BCP
• Acquisition of the Portuguese generics supplier Ciclum Farma
• Acquisition of approx. 97.5% of the shares in the Russian pharmaceuticals company, Nizhpharm

2004

• Acquisition of a portfolio of Branded Products in Italy
• De facto 1:1 stock split
• Early Entry Mirtazapine

2003

• Capital measures raised total net funds of EUR 256.4 million
• Acquisition of a package of branded products from redinomedica, for the German OTC market
• Acquisition of UK generics supplier Schein Pharmaceuticals with generics sales line Genus
• Acquisition of 60% stake in Italy’s NPA, a sales specialist in the pharmacy sector
• For the first time: Market capitalization > EUR 1 billion

2002

• Start of operations in the USA with the sales company STADA Pharmaceuticals Inc. after acquiring the business of the US generics supplier MOVA Laboratories
• Acquisition of marketing and sales activities of Italian pharmaceutical company Crinos
• Acquisition of Spanish generics supplier Bayvit S.A.
• STADA increases stake in Spanish brand supplier Ciclum Farma to 100%
• Acquisition of numerous local branded products
• Conversion from German accounting standards (HGB) to IAS
• Inclusion in EuroSTOXX 600 stock index

2001

• Sales exceed the EUR 500 million threshold
• Conversion of preferred shares into registered common shares
• STADA common stock is included in the German mid-cap index, MDAX
• Majority investments in the Philippines (Croma Medic Ltd.)
• Start-up of biogenerics cooperation with DSM, utilizing private venture capital

2000

• Stock split 1:10 for common and preferred stock
• Acquisition of Clonmel Healthcare Ltd., the leader in the Irish generics market

1999

• Start-up of STADA Asiatic Co. Ltd., Bangkok
• Investment in Spain in Ciclum Farma, Madrid
• Start-up in Italy with EG S.p.A., Milan

1998

• Conclusion of the process of going public with registered common stock
• Acquisition in Denmark (PharmaCoDane Aps)
• Positioning as comprehensive supplier in the health care market with the acquisition of oncologics (cell pharm) and a package of discretionary prescription brands from Fresenius

1997

• Beginning of process of going public with non-voting preferred stock

1996

• Purchase of ALIUD PHARMA as second generics line in Germany
• Expansion into France (EG Laboratoires EuroGenerics S.A.) and the Czech Republic (ALIUD PHARMA CZ s.r.o.)

1995

• Expansion of the STADA Group structure with market-oriented sales companies

1992

• Start-up in Asia with STADA Pharmaceuticals (Asia) Ltd. in Hong Kong

1991

• Acquisitions in the Netherlands (Centrafarm B.V.) and in Belgium (N.V. Eurogenerics S.A.)

1986

• Beginning of internationalization (Helvepharm AG/Switzerland, STADA Arzneimittel/Austria)

1975

• Entry into the emerging generics market

1970

• STADA becomes a stock corporation with registered shares exclusively for pharmacists

1956

• Move to the present location in Bad Vilbel

1948

• New beginning at the locations in Essen and Tübingen with products for self-medication

1895

• Founded in Dresden as a pharmacists’ cooperative